This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Exploring REGENXBIO Inc.'s RGX-202 for Duchenne Muscular Dystrophy (DMD)
Ticker(s): RGNXWho's the expert?
Institution: Children’s Hospital of Philadelphia
- Medical Director of the CHOP Pulmonary Function Testing (PFT) laboratory & Associate Professor of Clinical Pediatrics at UPENN.
- US PI in the SIDEROS study for Idebenone in patients with DMD.
- Clinical interests focus on chronic respiratory failure, the pulmonary manifestations of neuromuscular disease, and assessing and managing patients with complex chest wall and spine disease.
Interview GoalGaining expert opinion on RGX-202's interim results and understanding its implications on the treatment landscape of Duchenne Muscular Dystrophy (DMD)
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
